[Fibrotic remodeling of the lung following lung and stem-cell transplantation]
- PMID: 33416936
- DOI: 10.1007/s00292-020-00898-2
[Fibrotic remodeling of the lung following lung and stem-cell transplantation]
Erratum in
-
Erratum: Ergänzung der Herausgeberschaft.Pathologe. 2021 Feb;42(1):102. doi: 10.1007/s00292-021-00917-w. Pathologe. 2021. PMID: 33481061 Free PMC article. German. No abstract available.
Abstract
Transplantation of solid organs and hematopoietic stem cells represents an important therapeutic option for a variety of end-stage pulmonary diseases, aggressive hematopoietic neoplasms, or severe immunodeficiencies. Although the overall survival following transplantation has generally improved over recent decades, long-time survival of lung and stem-cell transplant recipients is still alarmingly low with an average 5‑year survival rate of only 50-60%. Chronic allo-immunoreactions in general and pulmonary allo-immunoreactions with subsequent fibrosis in particular are major reasons for this poor outcome. Comparable patterns of fibrotic lung remodeling are observed following both lung and hematopoietic stem-cell transplantation. Besides the meanwhile well-established obliterative and functionally obstructive remodeling of the small airways - obliterative bronchiolitis - a specific restrictive subform of fibrosis, namely alveolar fibroelastosis, has been identified. Despite their crucial impact on patient outcome, both entities can be very challenging to detect by conventional histopathological analysis. Their underlying mechanisms are considered overreaching aberrant repair attempts to acute lung injuries with overactivation of (myo-) fibroblasts and excessive and irreversible deposition of extracellular matrix. Of note, the underlying molecular mechanisms are widely divergent between these two morphological entities and are independent of the underlying clinical setting.Further comprehensive investigations of these fibrotic alterations are key to the development of much-needed predictive diagnostics and curative concepts, considering the high mortality of pulmonary fibrosis following transplantation.
Wenngleich die Sterblichkeit von Patienten nach Lungen- oder Stammzelltransplantation deutlich verbessert werden konnte, weisen beide Therapieverfahren weiterhin eine hohe 5‑Jahres-Mortalität auf. Dies ist Folge insbesondere von Lungenerkrankungen als Ausdruck einer chronischen Alloimmunreaktion. Morphologisch stehen fibrosierende Parenchymveränderungen mit Umbau der Atemwege im Sinne einer Bronchiolitis obliterans oder Umbau des Alveolarparenchyms im Sinne einer alveolären Fibroelastose im Vordergrund. Molekulare Studien dokumentieren viele Parallelen, jedoch auch distinkte Unterschiede zwischen diesen klinisch und morphologisch deutlich divergierenden Entitäten. Es zeigt sich erneut, dass histomorphologisch abgrenzbare Muster des fibrotischen Parenchymumbaus für sich genommen unspezifisch, in Zusammenschau mit den klinisch-radiologischen Befunden jedoch bestimmten Entitäten mit zum Teil deutlich unterschiedlichen Prognosen und Therapien zuordenbar sind.Fortschritte des molekularen Verständnisses dieser Läsionen sind Grundlage für eine frühe Vorhersage und exaktere Diagnose irreversibler fibrotischer Veränderungen der Lunge und für die mögliche Entwicklung bisher fehlender Therapieoptionen.
Keywords: Alloimmune reactions; Alveolar fibroelastosis (AFE); Bronchiolitis obliterans (BO); Organ rejection; Organ transplantation.
References
Literatur
-
- Ackermann M, Stark H, Neubert L et al (2020) Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. Eur Respir J. https://doi.org/10.1183/13993003.00933-2019 - DOI - PubMed - PMC
-
- Alici IO, Yekeler E, Yazicioglu A et al (2015) A case of acute fibrinous and organizing pneumonia during early postoperative period after lung transplantation. Transplant Proc 47:836–840. https://doi.org/10.1016/j.transproceed.2015.02.002 - DOI - PubMed
-
- Barton LM, Duval EJ, Stroberg E et al (2020) COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol 153(6):725–733. https://doi.org/10.1093/ajcp/aqaa062 - DOI - PubMed
-
- Belperio JA, Keane MP, Burdick MD et al (2005) Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115:1150–1162. https://doi.org/10.1172/JCI200524233 - DOI - PubMed - PMC
-
- Belperio JA, Ross DJ, Strieter RM et al (2005) Role of CXCR2 / CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome find the latest version : role of CXCR2 / CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115:1150–1162. https://doi.org/10.1172/JCI200524233.1150 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
